Ascendiant initiated coverage of IGC Pharma with a Buy rating and $2.75 price target. The company has ;arge market opportunities for its five drugs to treat Alzheimer’s, the analyst tells investors in a research note. The firm believes expected positive clinical data and milestones in 2024 will be strong catalysts for the stock.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IGC:
- Rising High: Exclusive talk with house of brands Carma HoldCo
- Rising High: Exclusive talk with drug manufacturer Optimi Health
- IGC Pharma announces TGR-63 reduces agitation in ‘Alzheimer’s Mouse Model’
- Here’s What You Missed in Cannabis, Psychedelics This Week
- DEA says now conducting review of marijuana scheduling, Punchbowl reports
